STOCK TITAN
  1. Home
  2. Sec-filings
  3. SUPN
  4. [Form 4] SUPERNUS PHARMACEUTICALS, INC. Insider Trading Activity

Supernus (SUPN) SVP Bhatt logs RSU vesting, stock grants and tax withholding

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

SUPERNUS PHARMACEUTICALS, INC. senior vice president Padmanabh P. Bhatt reported a series of equity-related transactions in connection with restricted stock units and common stock on February 24, 2026. He disposed of restricted stock units back to the issuer in amounts of 1,125, 750 and 1,250 units, each representing the right to receive one share of common stock upon vesting.

On the same date, he acquired common stock through grants or awards of 1,125, 750 and 1,250 shares. The filing also shows tax-withholding dispositions of 581, 354 and 646 common shares, with shares withheld by the company at prices of $51.35 and $50.86 per share to satisfy tax obligations upon RSU vesting. Certain RSUs vest in four equal annual installments beginning on February 19, 2026, February 22, 2023 and February 22, 2025, and are settled in common stock.

Positive

  • None.

Negative

  • None.
Insider Bhatt Padmanabh P.
Role Sr. VP of IP, CSO
Type Security Shares Price Value
Disposition Restricted Stock Unit 1,125 $0.00 --
Disposition Restricted Stock Unit 750 $0.00 --
Disposition Restricted Stock Unit 1,250 $0.00 --
Grant/Award Common Stock 1,125 $0.00 --
Tax Withholding Common Stock 581 $51.35 $30K
Grant/Award Common Stock 750 $0.00 --
Tax Withholding Common Stock 354 $50.86 $18K
Grant/Award Common Stock 1,250 $0.00 --
Tax Withholding Common Stock 646 $50.86 $33K
Holdings After Transaction: Restricted Stock Unit — 3,375 shares (Direct); Common Stock — 16,025 shares (Direct)
Footnotes (1)
  1. Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2023. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bhatt Padmanabh P.
(Last) (First) (Middle)
C/O SUPERNUS PHARMACEUTICALS, INC.
9715 KEY WEST AVENUE
(Street)
ROCKVILLE MD 20850
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Sr. VP of IP, CSO
3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/24/2026 A 1,125 A $0 16,025 D
Common Stock 02/24/2026 F 581(1) D $51.35 15,444 D
Common Stock 02/24/2026 A 750 A $0 16,194 D
Common Stock 02/24/2026 F 354(1) D $50.86 15,840 D
Common Stock 02/24/2026 A 1,250 A $0 17,090 D
Common Stock 02/24/2026 F 646(1) D $50.86 16,444 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (2) 02/24/2026 D 1,125 (3) (3) Common Stock 1,125 $0 3,375 D
Restricted Stock Unit (2) 02/24/2026 D 750 (4) (4) Common Stock 750 $0 0 D
Restricted Stock Unit (2) 02/24/2026 D 1,250 (5) (5) Common Stock 1,250 $0 2,500 D
Explanation of Responses:
1. Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting.
2. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
3. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026.
4. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2023.
5. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025.
Remarks:
/s/ Timothy C. Dec, as attorney-in-fact 02/25/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did SUPN executive Padmanabh Bhatt report on February 24, 2026?

Padmanabh P. Bhatt reported multiple equity transactions on February 24, 2026, including dispositions of restricted stock units to the issuer and grants of common stock. The filing also shows common shares withheld by the company to cover tax obligations related to the vesting of those restricted stock units.

How many Supernus (SUPN) restricted stock units did Padmanabh Bhatt dispose of?

Padmanabh Bhatt reported issuer dispositions of restricted stock units in three blocks: 1,125 units, 750 units and 1,250 units. Each restricted stock unit represents the right to receive one share of Supernus common stock when it vests, according to the footnotes in the Form 4 filing.

What common stock awards did SUPN grant to Padmanabh Bhatt in this Form 4?

The Form 4 shows three grant or award acquisitions of Supernus common stock to Padmanabh Bhatt on February 24, 2026, in amounts of 1,125, 750 and 1,250 shares. These awards are separate from the restricted stock unit positions and related tax-withholding transactions described in the filing.

How were taxes handled on Padmanabh Bhatt’s SUPN stock vesting events?

Taxes were satisfied through share withholding. The company withheld 581, 354 and 646 shares of Supernus common stock to cover tax obligations, at prices of $51.35 and $50.86 per share. The footnotes state these shares were withheld in connection with restricted stock unit vesting events.

When do Padmanabh Bhatt’s SUPN restricted stock units vest and settle?

According to the filing, certain restricted stock units vest in four equal annual installments beginning on February 19, 2026, February 22, 2023 and February 22, 2025. Each restricted stock unit is settled in Supernus common stock as it vests, providing share delivery over several years.

What is Padmanabh Bhatt’s role at Supernus Pharmaceuticals (SUPN) in this Form 4?

The Form 4 identifies Padmanabh P. Bhatt as an officer of Supernus Pharmaceuticals with the title "Sr. VP of IP, CSO." This indicates he is a senior vice president focused on intellectual property and serves as chief scientific officer while holding directly owned equity reported in the filing.